[go: up one dir, main page]

TN2009000138A1 - Biaryl-ether-urees - Google Patents

Biaryl-ether-urees

Info

Publication number
TN2009000138A1
TN2009000138A1 TNP2009000138A TN2009000138A TN2009000138A1 TN 2009000138 A1 TN2009000138 A1 TN 2009000138A1 TN P2009000138 A TNP2009000138 A TN P2009000138A TN 2009000138 A TN2009000138 A TN 2009000138A TN 2009000138 A1 TN2009000138 A1 TN 2009000138A1
Authority
TN
Tunisia
Prior art keywords
compounds
biaryl
urea
ether
preparation
Prior art date
Application number
TNP2009000138A
Other languages
English (en)
Inventor
Lorraine Kathleen Fay
Douglas Scott Johnson
Scott Edward Lazerwith
Mark Anthony Morris
Lijuan Jane Wang
Marvin Jay Meyers
Suzanne Ross Kesten
Cory Michael Stiff
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39314409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000138A1 publication Critical patent/TN2009000138A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne les composés de formule (I) ou un de leurs sels pharmaceutiquement acceptables, des procédés pour la préparation des composés, les intermédiaires utilisés dans la préparation des composés ; des compositions contenant les composés et des utilisations des composés dans le traitement de maladies ou d'affections associées à une activité d' hydrolase d'amide d'acide gras (FAAH).
TNP2009000138A 2006-10-18 2009-04-14 Biaryl-ether-urees TN2009000138A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82996606P 2006-10-18 2006-10-18
US96521007P 2007-08-17 2007-08-17
PCT/IB2007/003202 WO2008047229A2 (fr) 2006-10-18 2007-10-05 Composés d'urée de bisaryle éther

Publications (1)

Publication Number Publication Date
TN2009000138A1 true TN2009000138A1 (fr) 2010-10-18

Family

ID=39314409

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000138A TN2009000138A1 (fr) 2006-10-18 2009-04-14 Biaryl-ether-urees

Country Status (38)

Country Link
US (1) US8044052B2 (fr)
EP (1) EP2076508B1 (fr)
JP (1) JP4434313B2 (fr)
KR (1) KR101181194B1 (fr)
CN (1) CN101595102B (fr)
AP (1) AP2780A (fr)
AR (1) AR063331A1 (fr)
AT (1) ATE493984T1 (fr)
AU (1) AU2007311591B2 (fr)
BR (1) BRPI0717596B8 (fr)
CA (1) CA2663984C (fr)
CL (1) CL2007003000A1 (fr)
CR (2) CR10701A (fr)
CY (1) CY1111170T1 (fr)
DE (1) DE602007011793D1 (fr)
DK (1) DK2076508T3 (fr)
EA (1) EA015488B1 (fr)
ES (1) ES2357340T3 (fr)
GE (1) GEP20125425B (fr)
HN (1) HN2007000407A (fr)
HR (1) HRP20110158T1 (fr)
IL (1) IL197664A (fr)
MA (1) MA30801B1 (fr)
ME (1) ME01308B (fr)
MX (1) MX2009004233A (fr)
MY (1) MY145460A (fr)
NO (1) NO342266B1 (fr)
NZ (1) NZ575624A (fr)
PE (1) PE20081265A1 (fr)
PL (1) PL2076508T3 (fr)
PT (1) PT2076508E (fr)
RS (2) RS51647B (fr)
SI (1) SI2076508T1 (fr)
TN (1) TN2009000138A1 (fr)
TW (1) TWI404715B (fr)
UY (1) UY30649A1 (fr)
WO (1) WO2008047229A2 (fr)
ZA (1) ZA200902548B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2937341T1 (sl) 2004-12-30 2017-10-30 Janssen Pharmaceutica N.V. Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
MX2009004233A (es) 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
WO2009126691A1 (fr) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibiteurs d'hydrolase d'amide d'acide gras
JP2011518144A (ja) * 2008-04-17 2011-06-23 ファイザー・インク Ｆａａｈ阻害剤として有用な４−ベンジリデン−３−メチルピペリジンアリールカルボキサミド化合物
EP2276735A1 (fr) * 2008-04-17 2011-01-26 Pfizer Inc. Composés d'éther-benzylidène-pipéridine-aryl-carboxamide utiles comme inhibiteurs de faah
WO2009127948A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composés aryl carboxamides à 5 éléments de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
WO2009127949A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composés aryl carboxamides de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
CA2719784A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composes d'ether-benzylidene-piperidine-aryl a 5 chainons-carboxamide utiles comme inhibiteurs de faah
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068452A1 (fr) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Modulateurs à base d’urée à substitution hétéroaryle d'amide d’acide gras hydrolase
WO2010064597A1 (fr) * 2008-12-01 2010-06-10 武田薬品工業株式会社 Dérivé de pipéridine
EA020460B1 (ru) 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
EP2416660B1 (fr) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibiteurs d'amide d'hydrolase d'acide gras
WO2010118159A1 (fr) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibiteurs d'hydrolase d'amide d'acide gras
WO2010124113A1 (fr) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anticorps anti-acide gras amide hydrolase 2 et leurs utilisations
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8901111B2 (en) 2009-06-05 2014-12-02 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
KR101820541B1 (ko) 2009-09-09 2018-02-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 8-옥소디히드로퓨린 유도체
WO2011077313A1 (fr) 2009-12-22 2011-06-30 Pfizer Inc. Pipéridinecarboxamides en tant qu'inhibiteurs de mpges - 1
WO2011085216A2 (fr) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour traiter la maladie de parkinson et le syndrome des jambes sans repos
EP2531511A1 (fr) 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Inhibiteurs de l'hydrolase d'amides d'acides gras
CA2789606A1 (fr) 2010-02-25 2011-09-01 Pfizer Limited Analogues peptidiques en tant qu'agonistes des recepteurs opioides
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
EP2590951B1 (fr) 2010-07-09 2015-01-07 Pfizer Limited Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
WO2012004714A2 (fr) 2010-07-09 2012-01-12 Pfizer Limited Composés chimiques
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2801032A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant
CA2804716A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
WO2012095781A1 (fr) 2011-01-13 2012-07-19 Pfizer Limited Dérivés d'indazole comme inhibiteurs des canaux sodiques
EA201391239A1 (ru) 2011-04-05 2014-03-31 Пфайзер Лимитед Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
CA2840317C (fr) 2011-07-13 2016-11-01 Pfizer Limited Analogues d'enkephaline
AU2012311061B2 (en) * 2011-09-23 2016-08-18 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
WO2013054185A1 (fr) 2011-10-13 2013-04-18 Pfizer, Inc. Dérivés de pyrimidine et de pyridine utiles en thérapie
PH12014500919A1 (en) 2011-10-26 2014-06-09 Pfizer Ltd (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
IN2014DN03063A (fr) 2011-10-28 2015-05-15 Inhibitaxin Ltd
WO2013088315A1 (fr) 2011-12-15 2013-06-20 Pfizer Limited Dérivés de sulfonamide
WO2013093688A1 (fr) 2011-12-19 2013-06-27 Pfizer Limited Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
ES2548228T3 (es) 2012-02-03 2015-10-15 Pfizer Inc Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
WO2014053968A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
CA2885247A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinases apparentes a la tropomyosine
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
EP3319968A1 (fr) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
IL304017A (en) 2017-01-06 2023-08-01 Yumanity Therapeutics Inc Methods for treating neurological disorders
TWI770104B (zh) 2017-01-11 2022-07-11 美商羅登醫療公司 組蛋白去乙醯酶雙環抑制劑
ES2882905T3 (es) 2017-06-30 2021-12-03 Amgen Inc Síntesis de omecamtiv mecarbil
PL3664802T3 (pl) 2017-08-07 2022-07-11 Alkermes, Inc. Bicykliczne inhibitory deacetylaz histonowych
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
AU2019323450B2 (en) * 2018-08-24 2025-04-10 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
EA202192047A1 (ru) * 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
JP2024529022A (ja) * 2021-08-04 2024-08-01 ジャズ ファーマシューティカルズ アイルランド リミテッド 心的外傷後ストレス障害を治療する方法
TW202410897A (zh) * 2022-07-15 2024-03-16 愛爾蘭商爵士製藥愛爾蘭公司 聯芳醚脲化合物
WO2024167423A1 (fr) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Composés de dégradation de gspt1
US12410137B2 (en) 2023-07-17 2025-09-09 Apogee Pharmaceuticals, Inc. Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB138405A (en) 1919-01-16 1920-02-12 Thomas Thompson Improvements in or relating to suction or delivery valves for pumps
GB1138405A (en) 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3576810A (en) 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
GB1260886A (en) 1969-06-20 1972-01-19 Ici Ltd Process for aryloxymethylmorpholine derivatives
BE759013R (fr) 1969-11-17 1971-05-17 Ici Ltd Derives de la
BE758766A (fr) 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4116665A (en) 1976-04-02 1978-09-26 Eli Lilly And Company Method of regulating the growth of aquatic weeds with pyridine derivatives
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8424979D0 (en) 1984-10-03 1984-11-07 Wyeth John & Brother Ltd Benzenesulphonamide derivatives
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
SG44565A1 (en) 1991-12-18 1997-12-19 Schering Corp Imidazoylalkyl substituted with a six membered nitrogen containint heterocyclic ring
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995006037A1 (fr) 1993-08-27 1995-03-02 Vrije Universiteit Nouveaux derives d'imidazoles a activite agoniste ou antagoniste du recepteur h3 a l'histamine
CZ288002B6 (cs) 1995-01-11 2001-03-14 Samjin Pharmaceutical Co., Ltd. Piperazinové deriváty a farmaceutický prostředek s protinádorovou aktivitou je obsahující
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6184242B1 (en) 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
DE69912590T2 (de) 1998-04-01 2004-09-16 Janssen Pharmaceutica N.V. Pde-iv-hemmende pyridin-derivate
CN100340552C (zh) 1998-12-29 2007-10-03 法玛西雅厄普约翰美国公司 芳基醚的制备方法
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
BR0009437A (pt) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
YU54402A (sh) 2000-01-18 2005-11-28 Pfizer Products Inc. Antagonisti faktora otpuštanja kortikotropina
JP2003522767A (ja) 2000-02-11 2003-07-29 バーテックス ファーマシューティカルズ インコーポレイテッド ニューロン損傷の処置または予防のためのピペラジンおよびピペリジン誘導体
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1263758A2 (fr) 2000-03-03 2002-12-11 Ortho-McNeil Pharmaceutical, Inc. Derives de 3-(diarylmethylene)-8-azabicyclo 3.2.1]octane
JP2001303987A (ja) 2000-04-21 2001-10-31 Toyota Motor Corp 筒内噴射式内燃機関のスロットル制御装置
WO2001095856A2 (fr) 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Derive d'uree en tant qu'agent anticancereux et son procede de preparation
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
WO2002062963A2 (fr) 2001-02-08 2002-08-15 Nps Pharmaceuticals, Inc. Procedes et composes pour le traitement de troubles neurologiques ou neuropsychiatriques, et procedes relatifs a l'identication de composes visant a traiter ces troubles
AU2002333233A1 (en) 2001-07-09 2003-01-29 Pharmacia Italia Spa Interaction inhibitors of tcf-4 with beta-catenin
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US20040034101A1 (en) 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP3865626B2 (ja) 2001-11-08 2007-01-10 株式会社ベステックスキョーエイ パイプ部材
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
US20040063726A1 (en) 2002-02-08 2004-04-01 Artman Linda D Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
IL164004A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv Piperazinyl-,pipertifinyl-and morpholinyl-derivatives as novel inhibitors of histone deacetylase
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003080060A1 (fr) 2002-03-20 2003-10-02 Schering Aktiengesellschaft Inhibiteurs antithrombotiques de pai-1, a base de piperazine substituee
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
US20070134753A1 (en) 2002-10-21 2007-06-14 Barbier Ann J Assay for determining the activity of fatty acid amide hydrolase
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004087646A2 (fr) 2003-04-03 2004-10-14 Merck Patent Gmbh Composes carbonyle
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301443D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0325287D0 (en) 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
BRPI0417345A (pt) * 2003-12-03 2007-03-13 Cytopia Res Pty Ltd compostos inibidores de quìnase baseados em azola, composições e seus usos
WO2005075472A1 (fr) 2004-02-03 2005-08-18 Janssen Pharmaceutica, N.V. Derives de 3-(diheteroarylnethylene)-8-azabicyclo[3.2.1]octane et de 3-(aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane
AU2005233569B2 (en) * 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1742626A2 (fr) 2004-04-23 2007-01-17 The Regents of The University of California Composes et procedes de traitement de la douleur non inflammatoire au moyen d'agonistes de pparalpha
SE0401343D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006034341A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
WO2006035303A1 (fr) 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Antagonistes de recepteurs muscariniques
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1655297A1 (fr) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Pyridineurées de nicotinamide commes inhibiteurs du recepteur kinase du facteur de croissance endothéliale vasculaire (VEGF)
EP1657241A1 (fr) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
GT200500375A (es) 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
JP4980928B2 (ja) 2004-12-24 2012-07-18 プロシディオン・リミテッド Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用
RU2423349C2 (ru) 2004-12-24 2011-07-10 Астразенека Аб Гетероциклические соединения в качестве антагонистов ccr2b
SI2937341T1 (sl) * 2004-12-30 2017-10-30 Janssen Pharmaceutica N.V. Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
EP1851328A1 (fr) 2005-02-10 2007-11-07 Warner-Lambert Company Llc Analyse d'hydrolase d'amide d'acide gras
WO2006087305A1 (fr) * 2005-02-16 2006-08-24 Neurosearch A/S Derives aryle diazabicycliques et utilisation medicale
ES2433290T3 (es) 2005-02-17 2013-12-10 Astellas Pharma Inc. Derivados de piperazina para el tratamiento de la incontinencia urinaria y el dolor
WO2006116773A2 (fr) 2005-04-28 2006-11-02 The Regents Of The University Of California Procedes, compositions et composes de modulation de la lipase de monoacylglycerol, de douleurs et de troubles lies au stress
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006129842A1 (fr) 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. Nouveau derive aminopyridine ayant une activite d’inhibition selective de l’aurora-a
JPWO2006137465A1 (ja) 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
WO2007023882A1 (fr) 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Dérivé ayant une activité agoniste vis-à-vis du ppar
US7131609B1 (en) 2005-08-31 2006-11-07 Kimberly-Clark Worldwide, Inc. Dispenser for sheet material
AU2006332675A1 (en) 2005-12-29 2007-07-12 N.V. Organon Inhibitors of fatty acid amide hydrolase
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
WO2007103456A2 (fr) 2006-03-06 2007-09-13 Trimeris, Inc. Derives de piperazine et piperidine biaryle
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
WO2008005368A2 (fr) 2006-06-30 2008-01-10 Abbott Laboratories Pipérazines en tant qu'antagonistes de p2x7
WO2008024139A2 (fr) 2006-08-18 2008-02-28 N.V. Organon Inhibiteurs d'hydrolase des amides d'acides gras
WO2008021625A2 (fr) 2006-08-18 2008-02-21 N.V. Organon Inhibiteur de faah et agent analgésique, anti-inflammatoire ou anti-pyrétique combinés
US7888394B2 (en) 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
CA2665804A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. Compose d'uree ou sel dudit compose
US20080089845A1 (en) 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
US20090099240A1 (en) 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
MX2009004233A (es) 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
CA2674359A1 (fr) 2006-11-20 2008-05-29 N.V. Organon Inhibiteurs stabilises metaboliquement d'hydrolase d'amides d'acide gras
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
WO2008153752A2 (fr) 2007-05-25 2008-12-18 Janssen Pharmaceutica N.V. Modulateurs de l'urée substitués hétéroaryle damide 'hydrolase d'acides gras

Also Published As

Publication number Publication date
HRP20110158T1 (hr) 2011-04-30
CL2007003000A1 (es) 2008-06-13
ZA200902548B (en) 2010-03-31
MA30801B1 (fr) 2009-10-01
CA2663984A1 (fr) 2008-04-24
HK1139652A1 (en) 2010-09-24
MY145460A (en) 2012-02-15
EA200970296A1 (ru) 2009-10-30
AU2007311591B2 (en) 2010-10-07
CN101595102B (zh) 2013-08-07
AR063331A1 (es) 2009-01-21
NZ575624A (en) 2012-02-24
CN101595102A (zh) 2009-12-02
CA2663984C (fr) 2012-02-21
EP2076508B1 (fr) 2011-01-05
RS51647B (sr) 2011-10-31
PT2076508E (pt) 2011-03-07
JP2010506896A (ja) 2010-03-04
KR20090061051A (ko) 2009-06-15
CY1111170T1 (el) 2015-06-11
AP2009004821A0 (en) 2009-04-30
WO2008047229A2 (fr) 2008-04-24
AP2780A (en) 2013-09-30
ME01308B (me) 2013-12-20
ATE493984T1 (de) 2011-01-15
EP2076508A2 (fr) 2009-07-08
CR20140313A (es) 2014-07-28
TWI404715B (zh) 2013-08-11
IL197664A0 (en) 2009-12-24
ES2357340T3 (es) 2011-04-25
BRPI0717596A2 (pt) 2013-10-29
PE20081265A1 (es) 2008-09-17
JP4434313B2 (ja) 2010-03-17
AU2007311591A1 (en) 2008-04-24
MX2009004233A (es) 2009-08-12
RS20090154A (sr) 2010-10-31
WO2008047229A3 (fr) 2008-09-04
US20080261941A1 (en) 2008-10-23
TW200825062A (en) 2008-06-16
CR10701A (es) 2009-04-30
KR101181194B1 (ko) 2012-09-18
PL2076508T3 (pl) 2011-05-31
BRPI0717596B8 (pt) 2021-05-25
GEP20125425B (en) 2012-03-26
DE602007011793D1 (de) 2011-02-17
SI2076508T1 (sl) 2011-04-29
IL197664A (en) 2013-01-31
EA015488B1 (ru) 2011-08-30
US8044052B2 (en) 2011-10-25
UY30649A1 (es) 2008-05-31
BRPI0717596B1 (pt) 2020-04-14
DK2076508T3 (da) 2011-02-21
HN2007000407A (es) 2010-10-04
NO20091560L (no) 2009-05-15
NO342266B1 (no) 2018-04-30

Similar Documents

Publication Publication Date Title
TN2009000138A1 (fr) Biaryl-ether-urees
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN07022A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA30289B1 (fr) Dérivés d'amines
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TN2009000450A1 (fr) Derives de pyridine
TNSN99095A1 (fr) 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA31373B1 (fr) Composes amino-heterocycliques
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA32798B1 (fr) Acides naphtylacétiques